חברי משפחה
אין חברים להראות
על אודות
Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable—but only when programs are designed with precision and foresight.
הבא
(19)
עוקבים
(2)
חתוך את הדמות שלך
